Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/6/2023 | $140.00 | Outperform | TD Cowen |
| 6/12/2023 | $80.00 → $115.00 | Market Perform → Outperform | SVB Securities |
| 10/19/2022 | $75.00 | Buy | Guggenheim |
| 3/24/2022 | $91.00 | Buy | Goldman |
| 3/1/2022 | $39.00 → $34.00 | Neutral | Goldman Sachs |
| 12/9/2021 | $39.00 | Buy → Neutral | Goldman Sachs |
| 12/9/2021 | $110.00 → $37.00 | Outperform → Neutral | Robert W. Baird |
| 12/9/2021 | $112.00 → $68.00 | Overweight | Cantor Fitzgerald |
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company's previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). Approximately 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders, voting as a single class, entitled to vote at the special meeting, voted to approve the Merger, which represen
NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo
Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
TD Cowen initiated coverage of Reata Pharmaceuticals with a rating of Outperform and set a new price target of $140.00
SVB Securities upgraded Reata Pharmaceuticals from Market Perform to Outperform and set a new price target of $115.00 from $80.00 previously
Guggenheim initiated coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $75.00
15-12G - REATA PHARMACEUTICALS INC (0001358762) (Filer)
8-K - REATA PHARMACEUTICALS INC (0001358762) (Filer)
POSASR - REATA PHARMACEUTICALS INC (0001358762) (Filer)
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. "We are thrilled to welcome Dr. Ryder to Reata's board," said Warren Huff, Reata's Chief Executive Officer. "He is joining us at a critical point in Reata's development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia. His knowledge will be invaluable to help us achieve our mission in developing innovative therapies that change patients' lives for the bett
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a
SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through the End of 2026 Focus on Neurology Pipeline; Announced Discontinuation of Bardoxolone CKD Programs Conference Call with Management on May 10, 2023, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)